KRYS News and Press, Krystal Biotech Inc. From 01/21/20

PITTSBURGH, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial officer, effective Ja...

Inflammation is a physiological part of the complex biological response of tissues to counteract various harmful signals. Inflammation involves diverse factors such as immune cells, blood vessels, and nerves as sources of mediators. Among these factors, serine proteases are key elements in both ...

PITTSBURGH, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman a...

Buying stocks just because they're going up is a great way to lose a lot of money, but that doesn't mean you should avoid every company that's signaling signs of success. These three small-cap biotech stocks have been rocketing higher all year and for good reasons. They're all heading toward th...

Continuing with the series of articles on gene therapy, this article will discuss the various delivery methods for gene therapies with a focus on viral vectors. What is transgene? A transgene is a new therapeutic DNA segment that is to be inserted into the host cell. In addition to the g...

Krystal Biotech (NASDAQ: KRYS ): Q3 GAAP EPS of -$0.25 beats by $0.14 . More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, “B-VEC”) KB105 Granted Fast Track Designation by the FDA Platform Patent for Delivering any Effector to the Skin Granted by USPTO PITTSBURGH, Nov. 04, 2019 (GLOBE NEWSWIRE) -...

In a final update on its Phase 1/2 clinical trial evaluating topical gene therapy bercolagene telserpavec (B-VEC) (formerly KB103) for the treatment of rare inherited skin disorder called dystrophic epidermolysis bullosa (DEB), Krystal Biotech (NASDAQ: KRYS ) announces a 90% (n=9/10) wound...

Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported. Nine out of 10 of the wounds closed completely (100% closure) following initial administrations of B-VEC. The average time to wound closure was 17.4 days....

PITTSBURGH, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products...